drugset / Trial / NCT02381236

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

NCT02381236 ↗

Phase 2 Completed 1 enrolled GenSpera, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).

Timeline

Start
2016-02
Primary completion
2016-12
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mipsagargin Other / unclassified — Intravenous

Indications